Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.
Two sensitive, selective, and precise stability-indicating, high-performance liquid chromatography and high-performance thin-layer chromatography methods have been developed for the determination of alfuzosin hydrochloride in the presence of its degradation products. Alfuzosin.HCl was subjected to stress alkaline, acidic, oxidative, thermal, and photo-degradation. The drug could be well separated from the degradation products upon applying the two methods. Separation by HPLC was achieved using an Xterra RP18 column and acetonitrile/0.02 M KH2PO4 (pH=3) in a ratio of 20:80 as mobile phase. The flow rate was 1 mL/min. The linearity range was 0.25 to 11 microg/mL with mean percentage recovery of 100.26 +/- 1.54. The HPTLC method used ALUGRAM Nano-SIL silica gel 60 F254 plates; the optimized mobile phase was methanol/ammonia (100:1.2). Quantitatively the spots were scanned densitometrically at 245 nm. A second order polynomial equation was used for the regression. The range was 0.5-7 microg/spot. The mean percentage recovery was 100.13 +/- 1.67. Two main degradation products were obtained in most stress conditions, separated, and identified by FT-IR and NMR spectral analysis, from which the degradation pathway was proposed. The two methods were validated according to the International Conference on Harmonization. In addition, the HPLC method was used to study the kinetics of alkaline and acid degradation of the drug.
Salah Fayed
Ahmed
A
Cairo University, Faculty of Pharmacy, Analytical Chemistry Department, Cairo, Egypt. fayedaeg@yahoo.com
Abdel-Aaty Shehata
Mostafa
M
Yehia Hassan
Nagiba
N
El-Weshahy
Soheir Ahmed
SA
D000317:Adrenergic alpha-Antagonists / Q000032:analysis*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid / Q000592:standards*; D002855:Chromatography, Thin Layer / Q000592:standards*; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011799:Quinazolines / Q000032:analysis*; D012015:Reference Standards; D012680:Sensitivity and Specificity
D000317:Adrenergic alpha-Antagonists; D004364:Pharmaceutical Preparations; D011799:Quinazolines; C047638:alfuzosin